Please see below for a list of search results.
Faecal microbiota transplants (FMT) are recognised as an emerging treatment for recurrent Clostridium difficile infections in patients where antibiotic and other lines of treatment have failed.
The HTA and MHRA have agreed to extend their existing policy relating to dendritic cells. This extended policy will allow collection of blood as a starting material for an ATMP to be performed under either a Tissues and Cells or Blood Establishment Licence.
Guidance for establishments on meeting HTA licensing requirements for the procurement of tumour samples to be used as a starting material in the manufacture of an Advanced Therapy Medicinal Product (ATMP).
From the 4 January the HTA web Portal is open to collect annual activity data from organisations with an HTA human application licence. We are requesting data for the period covering 1 January to 31 December 2015.
The HTA is the UK Competent Authority for the purposes of the EU Tissues and Cells Directives, which set standards of quality and safety in relation to human tissues and cells intended for human application.
The HTA was asked to share a letter written to the University of Bristol regarding a process taking place at the university in 2008, as part of a process to create an artificial trachea for transplant
The European Commission has launched the web-based EU Coding Platform. The platform is free to access and is designed to help build the Single European Code (SEC) to be allocated and applied to tissues and cells.The EU Coding Platform contains two compendia:
The HTA was asked for details of serious adverse events and reactions (SAEARs) across multiple types of human application activities, broken down by year.